Mon, April 22, 2013
Sun, April 21, 2013
Fri, April 19, 2013
Thu, April 18, 2013
Wed, April 17, 2013
Tue, April 16, 2013
Mon, April 15, 2013
Fri, April 12, 2013
Thu, April 11, 2013
[ Thu, Apr 11th 2013 ]: Market Wire
15 PM EDT
Wed, April 10, 2013
Tue, April 9, 2013
[ Tue, Apr 09th 2013 ]: Market Wire
30 a.m. ET
Mon, April 8, 2013
Sat, April 6, 2013
Fri, April 5, 2013
Thu, April 4, 2013
Wed, April 3, 2013
Tue, April 2, 2013
Mon, April 1, 2013
Fri, March 29, 2013
Thu, March 28, 2013
Wed, March 27, 2013
Tue, March 26, 2013
Mon, March 25, 2013
Sun, March 24, 2013
Fri, March 22, 2013

The Law Firm of Levi &;; Korsinsky Notifies Investors With Losses on Their Investment in Incyte Corporation of Class

  Copy link into your clipboard //health-fitness.news-articles.net/content/2013/ .. r-investment-in-incyte-corporation-of-class.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

April 05, 2013 14:34 ET

SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky Notifies Investors With Losses on Their Investment in Incyte Corporation of Class Action Lawsuit and the May 6, 2013 Lead Plaintiff Deadline

NEW YORK, NY--(Marketwired - Apr 5, 2013) - Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Delaware on behalf of investors who purchased Incyte Corporation ("Incyte" or the "Company") (NASDAQ: [ INCY ]) stock between April 26, 2012 and August 1, 2012 (the "Class Period").

For more information, click here: [ http://zlk.9nl.com/incyte-incy/ ]. 

According to the complaint, Incyte's reported fourth quarter 2011 and first quarter 2012 sales were artificially inflated due to a large number of advanced-stage myelofibrosis patients being prescribed the drug upon FDA approval in November 2011 -- patients who had been too sick to participate in the clinical trials.

On August 2, 2012, Incyte disclosed that Jakafi sales growth had been much softer during the second quarter of 2012 than investors had been led to expect. Defendants also disclosed that many of the new patients prescribed Jakafi were so sick they would not have been eligible for the Phase III trial. Defendants conceded that while prescriptions to these patients had increased sales revenues, these were not revenues that would continue for the suggested three years on average that defendants claimed, as certain patients died. In response to these disclosures, the price of Incyte stock fell from its August 1, 2012 close of $24.92 per share to close at $19.57 per share on August 2, 2012.

If you suffered a loss in Incyte you have until May 6, 2013 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [ jlevi@zlk.com ] or by telephone at (877) 363-5972, or visit [ http://zlk.9nl.com/incyte-incy/ ].

Levi & Korsinsky is a national firm with offices in New York, New Jersey, and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.